

REMARKS**I. RESPONSE TO RESTRICTION REQUIREMENT**

1. In response to the Restriction Requirement, Applicants elect Group I without traverse. Applicants reserve the right to pursue claims drawn to the subject matter of Groups II-V in one or more divisional application(s).

2. With respect to the election of species requirements set forth at pages 4-7 of the Office Action (items 3 and 4 of the Office Action), Applicants elect the species Acetaminophen and liver necrosis, without traverse.

However, Applicants respectfully request that additional toxic effects recited in dependent claims 20, 21 and 66-68 (“carcinogenesis, cholestasis, hepatitis, liver enlargement, inflammation, liver necrosis, liver steatosis, and peroxisome proliferation”) be searched in this application.

Applicants also respectfully request that additional hepatotoxins recited in dependent claims 22, 47 and 69 (“acetaminophen, 2-acetylaminofluorene (2-AAF), acyclovir, ANIT, AY-25329, BI liver toxin, chloroform, bicalutamide, carbon tetrachloride, chloroform, CI-1000, clofibrate, colchicine, CPA, diclofenac, diflunisal, dimethylnitrosamine (DMN), dioxin, 17 β -ethinylestradiol, gemfibrozil, hydrazine, indomethacin, LPS, menadione, phenobarbital, tacrine, thioacetamide, valproate, Wy-14643 and zileuton”) be searched in this application.

3. In response to the gene election requirement at page 3 of the Office Action, Applicants elect the following sequences (one from each of Tables 5A-5WWW as suggested by the Examiner at page 4 of the Office Action) with traverse:

<u>TABLE 5</u>	<u>GLGC ID</u>	<u>SEQ ID NO</u>
A	24237	130
B	2459	1089
C	17361	365
D	24437	3304
E	2515	2995
F	10611	2278
G	20818	4184
H	21051	2839

I	4234	3626
J	21848	3932
K	15127	3879
L	9128	2100
M	573	2558
N	1794	3221
O	20589	3097
P	16457	3961
Q	14664	4031
R	14664	4031
S	1698	3247
T	9348	1740
U	17758	3958
V	22852	2346
W	3431	2218
X	15987	420
Y	2084	1165
Z	21968	954
AA	21968	954
BB	2248	2046
CC	2248	2046
DD	21098	3968
EE	13222	1824
FF	14595	536
GG	12306	891
HH	6143	3912
II	10611	2278
JJ	9604	1700
KK	9604	1700
LL	23699	3058
MM	23710	3223
NN	20864	3236
OO	2088	2472
PP	14887	2725
QQ	14887	2725
RR	24300	2399
SS	21874	2693
TT	12160	168
UU	20744	3083
VV	14124	371
WW	14033	1434
XX	23698	3058
YY	17758	3958
ZZ	23262	2393
AAA	23262	2393
BBB	22370	864
CCC	4196	685
DDD	12160	168
EEE	4011	3643
FFF	20983	1566
GGG	22929	1709

HHH	20741	1241
III	6532	2654
JJJ	20529	3309
KKK	22840	1325
LLL	20915	3472
MMM	4011	3643
NNN	15606	877
OOO	1246	3024
PPP	2485	142
QQQ	2485	142
RRR	18742	1886
SSS	20915	3472
TTT	23710	3223
UUU	15125	3879
VVV	22929	1709
WWW	18564	3171

This requirement is being traversed because a restriction on the basis of individual sequences is not warranted here under the unity of invention standards (the present application being a national stage application of PCT/US03/03194), especially in light of the election of species requirement. The Examiner is respectfully requested to search the claims on the basis of the species election set forth above (e.g., the toxic effect and hepatotoxin).

In addition, the claims have been amended to more clearly set forth the unity of invention, as discussed further below.

II. AMENDMENTS TO THE CLAIMS

In this Amendment: claims 1, 3-5, 7-10, 20-22, 46-49, 53-56, and 61 are amended; claims 2, 6, 11, 18, 19, 23-45, 50-52, 57, and 62-65 are canceled; and claims 66-69 are new.

Claims 11, 22, 23-45, 47, 50-52, 57-60, 64, and 65, which are drawn to a non-elected invention, are being canceled without prejudice. Applicants reserve the right to pursue the subject matter of these claims in one or more divisional applications.

Independent claim 1 has been amended to more clearly define the unity of invention. The amendments to claim 1 are supported by at least: paragraphs [0005], [0006], and [0012] of the application as filed; paragraph [0187] and original claim 3; as well as original claim 19.

Additional amendments have been made to the claims to clarify the subject matter thereof.

New claims 66-69 parallel original claims 20 and 47, and are being added to facilitate examination in accordance with the election of species requirement.

No new matter has been introduced.

Entry and consideration of this Amendment are requested.

The Examiner is invited to contact the undersigned for resolution of any issues that may arise during prosecution of this application.


Please charge the fee for a one-month extension of time to Deposit Account 50-1283.
Please also credit any overpayments to Deposit Account 50-1283.

Dated: June 26, 2007

COOLEY GODWARD KRONISH LLP
ATTN: Patent Group
1200 19th Street, NW, 5th Floor
Washington, DC 20036
Tel: (202) 842-7800
Fax: (202) 842-7899

Respectfully submitted,
COOLEY GODWARD KRONISH LLP

By:



Mark L. Hayman
Reg. No. 51,793